Aprea Therapeutics (APRE) Proxy filing summary

Executive summary

• Annual meeting scheduled for June 16, 2026, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by June 15, 2026.

Voting matters and shareholder proposals

• Election of three Class I directors: Marc Duey, Richard Peters, M.D., and Bernd R. Seizinger, M.D., Ph.D.

• Ratification of EisnerAmper LLP as independent registered public accounting firm for fiscal year 2026.

• Approval of a reverse stock split at a ratio between one-for-three and one-for-eight, with the exact ratio and timing at the Board's discretion.

• Non-binding advisory vote on executive compensation and on the frequency of future say-on-pay votes.

• Approval to adjourn the meeting if additional proxies are needed for the reverse stock split proposal.

Board of directors and corporate governance

• Board recommends voting in favor of all proposals, including director elections and corporate actions.